|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:UBQLN4-AHCYL1 (FusionGDB2 ID:96412) |
Fusion Gene Summary for UBQLN4-AHCYL1 |
Fusion gene summary |
Fusion gene information | Fusion gene name: UBQLN4-AHCYL1 | Fusion gene ID: 96412 | Hgene | Tgene | Gene symbol | UBQLN4 | AHCYL1 | Gene ID | 56893 | 10768 |
Gene name | ubiquilin 4 | adenosylhomocysteinase like 1 | |
Synonyms | A1U|A1Up|C1orf6|CIP75|UBIN | DCAL|IRBIT|PPP1R78|PRO0233|XPVKONA | |
Cytomap | 1q22 | 1p13.3 | |
Type of gene | protein-coding | protein-coding | |
Description | ubiquilin-4ataxin-1 interacting ubiquitin-like proteinataxin-1 ubiquitin-like interacting proteinataxin-1 ubiquitin-like-interacting protein A1Uconnexin43-interacting protein of 75 kDa | S-adenosylhomocysteine hydrolase-like protein 1DC-expressed AHCY-like moleculeIP(3)Rs binding protein released with IP(3)S-adenosyl homocysteine hydrolase homologS-adenosyl-L-homocysteine hydrolase 2adenosylhomocysteinase 2adoHcyase 2dendritic cell | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | . | O43865 | |
Ensembl transtripts involved in fusion gene | ENST00000368309, ENST00000472638, | ENST00000475081, ENST00000359172, ENST00000393614, ENST00000369799, | |
Fusion gene scores | * DoF score | 4 X 5 X 4=80 | 11 X 13 X 4=572 |
# samples | 5 | 12 | |
** MAII score | log2(5/80*10)=-0.678071905112638 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(12/572*10)=-2.25298074116987 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: UBQLN4 [Title/Abstract] AND AHCYL1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | UBQLN4(156011275)-AHCYL1(110551655), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | UBQLN4 | GO:0006974 | cellular response to DNA damage stimulus | 30612738 |
Hgene | UBQLN4 | GO:0032434 | regulation of proteasomal ubiquitin-dependent protein catabolic process | 27113755 |
Hgene | UBQLN4 | GO:2000042 | negative regulation of double-strand break repair via homologous recombination | 30612738 |
Tgene | AHCYL1 | GO:0006378 | mRNA polyadenylation | 19224921 |
Tgene | AHCYL1 | GO:0031440 | regulation of mRNA 3'-end processing | 19224921 |
Tgene | AHCYL1 | GO:0038166 | angiotensin-activated signaling pathway | 20584908 |
Tgene | AHCYL1 | GO:0051592 | response to calcium ion | 18829453 |
Fusion gene breakpoints across UBQLN4 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across AHCYL1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | PRAD | TCGA-VP-A87K | UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + |
ChimerDB4 | PRAD | TCGA-VP-A87K | UBQLN4 | chr1 | 156011276 | - | AHCYL1 | chr1 | 110551656 | + |
Top |
Fusion Gene ORF analysis for UBQLN4-AHCYL1 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5CDS-3UTR | ENST00000368309 | ENST00000475081 | UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + |
5CDS-3UTR | ENST00000368309 | ENST00000475081 | UBQLN4 | chr1 | 156011276 | - | AHCYL1 | chr1 | 110551656 | + |
5CDS-5UTR | ENST00000368309 | ENST00000359172 | UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + |
5CDS-5UTR | ENST00000368309 | ENST00000359172 | UBQLN4 | chr1 | 156011276 | - | AHCYL1 | chr1 | 110551656 | + |
5CDS-5UTR | ENST00000368309 | ENST00000393614 | UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + |
5CDS-5UTR | ENST00000368309 | ENST00000393614 | UBQLN4 | chr1 | 156011276 | - | AHCYL1 | chr1 | 110551656 | + |
In-frame | ENST00000368309 | ENST00000369799 | UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + |
In-frame | ENST00000368309 | ENST00000369799 | UBQLN4 | chr1 | 156011276 | - | AHCYL1 | chr1 | 110551656 | + |
intron-3CDS | ENST00000472638 | ENST00000369799 | UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + |
intron-3CDS | ENST00000472638 | ENST00000369799 | UBQLN4 | chr1 | 156011276 | - | AHCYL1 | chr1 | 110551656 | + |
intron-3UTR | ENST00000472638 | ENST00000475081 | UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + |
intron-3UTR | ENST00000472638 | ENST00000475081 | UBQLN4 | chr1 | 156011276 | - | AHCYL1 | chr1 | 110551656 | + |
intron-5UTR | ENST00000472638 | ENST00000359172 | UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + |
intron-5UTR | ENST00000472638 | ENST00000359172 | UBQLN4 | chr1 | 156011276 | - | AHCYL1 | chr1 | 110551656 | + |
intron-5UTR | ENST00000472638 | ENST00000393614 | UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + |
intron-5UTR | ENST00000472638 | ENST00000393614 | UBQLN4 | chr1 | 156011276 | - | AHCYL1 | chr1 | 110551656 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000368309 | UBQLN4 | chr1 | 156011275 | - | ENST00000369799 | AHCYL1 | chr1 | 110551655 | + | 5274 | 1746 | 93 | 3218 | 1041 |
ENST00000368309 | UBQLN4 | chr1 | 156011276 | - | ENST00000369799 | AHCYL1 | chr1 | 110551656 | + | 5274 | 1746 | 93 | 3218 | 1041 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000368309 | ENST00000369799 | UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + | 0.001137937 | 0.998862 |
ENST00000368309 | ENST00000369799 | UBQLN4 | chr1 | 156011276 | - | AHCYL1 | chr1 | 110551656 | + | 0.001137937 | 0.998862 |
Top |
Fusion Genomic Features for UBQLN4-AHCYL1 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + | 6.97E-07 | 0.9999993 |
UBQLN4 | chr1 | 156011275 | - | AHCYL1 | chr1 | 110551655 | + | 6.97E-07 | 0.9999993 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for UBQLN4-AHCYL1 |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:156011275/chr1:110551655) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
. | AHCYL1 |
FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: Multifaceted cellular regulator which coordinates several essential cellular functions including regulation of epithelial HCO3(-) and fluid secretion, mRNA processing and DNA replication. Regulates ITPR1 sensitivity to inositol 1,4,5-trisphosphate, competing for the common binding site and acting as endogenous 'pseudoligand' whose inhibitory activity can be modulated by its phosphorylation status. Promotes the formation of contact points between the endoplasmic reticulum (ER) and mitochondria, facilitating transfer of Ca(2+) from the ER to mitochondria (PubMed:27995898). Under normal cellular conditions, functions cooperatively with BCL2L10 to limit ITPR1-mediated Ca(2+) release but, under apoptotic stress conditions, dephosphorylated which promotes dissociation of both AHCYL1 and BCL2L10 from mitochondria-associated endoplasmic reticulum membranes, inhibits BCL2L10 interaction with ITPR1 and leads to increased Ca(2+) transfer to mitochondria which promotes apoptosis (PubMed:27995898). In the pancreatic and salivary ducts, at resting state, attenuates inositol 1,4,5-trisphosphate-induced calcium release by interacting with ITPR1 (PubMed:16793548). When extracellular stimuli induce ITPR1 phosphorylation or inositol 1,4,5-trisphosphate production, dissociates from ITPR1 to interact with CFTR and SLC26A6, mediating their synergistic activation by calcium and cAMP that stimulates the epithelial secretion of electrolytes and fluid (By similarity). Also activates basolateral SLC4A4 isoform 1 to coordinate fluid and HCO3(-) secretion (PubMed:16769890). Inhibits the effect of STK39 on SLC4A4 and CFTR by recruiting PP1 phosphatase which activates SLC4A4, SLC26A6 and CFTR through dephosphorylation (By similarity). Mediates the induction of SLC9A3 surface expression produced by Angiotensin-2 (PubMed:20584908). Depending on the cell type, activates SLC9A3 in response to calcium or reverses SLC9A3R2-dependent calcium inhibition (PubMed:18829453). May modulate the polyadenylation state of specific mRNAs, both by controlling the subcellular location of FIP1L1 and by inhibiting PAPOLA activity, in response to a stimulus that alters its phosphorylation state (PubMed:19224921). Acts as a (dATP)-dependent inhibitor of ribonucleotide reductase large subunit RRM1, controlling the endogenous dNTP pool and ensuring normal cell cycle progression (PubMed:25237103). In vitro does not exhibit any S-adenosyl-L-homocysteine hydrolase activity (By similarity). {ECO:0000250|UniProtKB:B5DFN2, ECO:0000250|UniProtKB:Q80SW1, ECO:0000269|PubMed:16769890, ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:18829453, ECO:0000269|PubMed:19224921, ECO:0000269|PubMed:20584908, ECO:0000269|PubMed:25237103, ECO:0000269|PubMed:27995898}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | UBQLN4 | chr1:156011275 | chr1:110551655 | ENST00000368309 | - | 10 | 11 | 13_87 | 551 | 602.0 | Domain | Ubiquitin-like |
Hgene | UBQLN4 | chr1:156011275 | chr1:110551655 | ENST00000368309 | - | 10 | 11 | 192_229 | 551 | 602.0 | Domain | STI1 1 |
Hgene | UBQLN4 | chr1:156011275 | chr1:110551655 | ENST00000368309 | - | 10 | 11 | 230_261 | 551 | 602.0 | Domain | STI1 2 |
Hgene | UBQLN4 | chr1:156011275 | chr1:110551655 | ENST00000368309 | - | 10 | 11 | 393_440 | 551 | 602.0 | Domain | STI1 3 |
Hgene | UBQLN4 | chr1:156011275 | chr1:110551655 | ENST00000368309 | - | 10 | 11 | 444_476 | 551 | 602.0 | Domain | STI1 4 |
Hgene | UBQLN4 | chr1:156011276 | chr1:110551656 | ENST00000368309 | - | 10 | 11 | 13_87 | 551 | 602.0 | Domain | Ubiquitin-like |
Hgene | UBQLN4 | chr1:156011276 | chr1:110551656 | ENST00000368309 | - | 10 | 11 | 192_229 | 551 | 602.0 | Domain | STI1 1 |
Hgene | UBQLN4 | chr1:156011276 | chr1:110551656 | ENST00000368309 | - | 10 | 11 | 230_261 | 551 | 602.0 | Domain | STI1 2 |
Hgene | UBQLN4 | chr1:156011276 | chr1:110551656 | ENST00000368309 | - | 10 | 11 | 393_440 | 551 | 602.0 | Domain | STI1 3 |
Hgene | UBQLN4 | chr1:156011276 | chr1:110551656 | ENST00000368309 | - | 10 | 11 | 444_476 | 551 | 602.0 | Domain | STI1 4 |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000359172 | 0 | 17 | 318_322 | 0 | 484.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000359172 | 0 | 17 | 397_399 | 0 | 484.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000369799 | 0 | 17 | 318_322 | 40 | 531.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000369799 | 0 | 17 | 397_399 | 40 | 531.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000393614 | 0 | 17 | 318_322 | 0 | 484.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000393614 | 0 | 17 | 397_399 | 0 | 484.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000359172 | 0 | 17 | 318_322 | 0 | 484.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000359172 | 0 | 17 | 397_399 | 0 | 484.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000369799 | 0 | 17 | 318_322 | 40 | 531.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000369799 | 0 | 17 | 397_399 | 40 | 531.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000393614 | 0 | 17 | 318_322 | 0 | 484.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000393614 | 0 | 17 | 397_399 | 0 | 484.0 | Nucleotide binding | NAD | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000359172 | 0 | 17 | 281_448 | 0 | 484.0 | Region | NAD binding | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000359172 | 0 | 17 | 520_530 | 0 | 484.0 | Region | PDZ-binding | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000359172 | 0 | 17 | 65_92 | 0 | 484.0 | Region | PEST | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000369799 | 0 | 17 | 281_448 | 40 | 531.0 | Region | NAD binding | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000369799 | 0 | 17 | 520_530 | 40 | 531.0 | Region | PDZ-binding | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000369799 | 0 | 17 | 65_92 | 40 | 531.0 | Region | PEST | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000393614 | 0 | 17 | 281_448 | 0 | 484.0 | Region | NAD binding | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000393614 | 0 | 17 | 520_530 | 0 | 484.0 | Region | PDZ-binding | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000393614 | 0 | 17 | 65_92 | 0 | 484.0 | Region | PEST | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000359172 | 0 | 17 | 281_448 | 0 | 484.0 | Region | NAD binding | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000359172 | 0 | 17 | 520_530 | 0 | 484.0 | Region | PDZ-binding | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000359172 | 0 | 17 | 65_92 | 0 | 484.0 | Region | PEST | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000369799 | 0 | 17 | 281_448 | 40 | 531.0 | Region | NAD binding | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000369799 | 0 | 17 | 520_530 | 40 | 531.0 | Region | PDZ-binding | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000369799 | 0 | 17 | 65_92 | 40 | 531.0 | Region | PEST | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000393614 | 0 | 17 | 281_448 | 0 | 484.0 | Region | NAD binding | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000393614 | 0 | 17 | 520_530 | 0 | 484.0 | Region | PDZ-binding | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000393614 | 0 | 17 | 65_92 | 0 | 484.0 | Region | PEST |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | UBQLN4 | chr1:156011275 | chr1:110551655 | ENST00000368309 | - | 10 | 11 | 553_598 | 551 | 602.0 | Domain | UBA |
Hgene | UBQLN4 | chr1:156011276 | chr1:110551656 | ENST00000368309 | - | 10 | 11 | 553_598 | 551 | 602.0 | Domain | UBA |
Top |
Fusion Gene Sequence for UBQLN4-AHCYL1 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>96412_96412_1_UBQLN4-AHCYL1_UBQLN4_chr1_156011275_ENST00000368309_AHCYL1_chr1_110551655_ENST00000369799_length(transcript)=5274nt_BP=1746nt GTTGGAGGCGCAGAAGCCGAGCCGGGCCGGCCGGGCGGGCGGGGAGGAGGAGGAGCCGGGCGGGCTGGCGGGCGGCCGGGTGGCGGCGGC GGCATGGCGGAGCCGAGCGGGGCCGAGACGAGGCCCCCCATTCGGGTCACCGTCAAGACCCCCAAGGACAAGGAGGAAATTGTGATCTGC GATCGAGCCTCGGTCAAGGAGTTCAAAGAGGAAATCTCCCGGAGGTTTAAGGCTCAGCAGGATCAGCTGGTCCTGATCTTCGCAGGCAAG ATCCTCAAGGATGGGGACACACTGAACCAGCACGGAATCAAGGACGGGCTCACTGTCCATCTGGTCATCAAGACCCCTCAGAAGGCTCAA GATCCAGCTGCTGCCACTGCTTCTTCCCCCTCCACACCTGACCCTGCCTCAGCACCCTCCACCACGCCTGCTTCACCCGCCACCCCTGCC CAGCCCTCCACCTCTGGCAGTGCCTCTTCAGATGCTGGCAGTGGAAGCCGGAGGAGCAGTGGTGGGGGGCCCTCTCCGGGGGCTGGGGAG GGATCCCCCAGTGCTACTGCGTCCATACTCTCTGGCTTTGGGGGCATCCTGGGGCTGGGCAGCCTAGGCCTGGGCTCTGCCAACTTCATG GAGCTGCAGCAGCAGATGCAGCGGCAGCTGATGTCCAATCCTGAGATGCTGTCACAGATCATGGAGAACCCCCTGGTCCAGGATATGATG TCTAACCCTGATCTGATGCGTCACATGATTATGGCCAACCCCCAGATGCAGCAGTTGATGGAGCGGAACCCTGAGATCAGCCACATGCTC AATAACCCTGAACTCATGAGGCAGACAATGGAGCTTGCTCGGAATCCAGCCATGATGCAAGAGATGATGCGGAACCAGGACCGGGCCCTG AGCAACCTTGAGAGCATCCCTGGAGGGTATAATGCCCTCCGCCGCATGTACACGGACATCCAGGAGCCCATGTTCAGTGCTGCCCGGGAA CAGTTTGGCAACAATCCCTTCTCTTCCCTGGCCGGGAACTCCGACAGCTCATCCTCCCAGCCTCTGCGGACTGAGAATCGAGAGCCCCTC CCTAACCCCTGGAGCCCCTCGCCCCCCACCTCCCAGGCCCCCGGGTCCGGTGGGGAGGGCACCGGAGGATCGGGGACCAGCCAGGTGCAC CCGACAGTCTCGAACCCCTTTGGGATCAATGCGGCTAGCCTGGGGTCAGGGATGTTCAATAGCCCAGAAATGCAAGCCCTCCTCCAGCAG ATCTCTGAGAACCCCCAGCTGATGCAGAATGTGATCTCAGCACCCTACATGCGCAGCATGATGCAGACGCTTGCCCAGAACCCCGACTTT GCTGCTCAGATGATGGTGAATGTGCCGCTCTTCGCGGGGAACCCCCAACTGCAGGAGCAGCTCCGCCTGCAGCTCCCAGTCTTCCTGCAG CAGATGCAGAACCCAGAGTCACTCTCCATCCTTACCAATCCCCGAGCCATGCAGGCATTGCTGCAGATCCAGCAGGGACTACAGACCTTG CAGACCGAGGCCCCTGGGCTGGTACCCAGCCTTGGCTCCTTTGGGATATCCCGGACCCCAGCACCCTCAGCAGGCAGCAACGCAGGGTCT ACGCCCGAGGCCCCCACTTCCTCACCAGCCACGCCAGCCACATCTTCTCCAACAGGGGCTTCCAGCGCCCAGCAGCAACTCATGCAGCAG ATGATCCAGCTTTTGGCTGGAAGTGGAAACTCACAGCAAATCCAGTTTGCTGATGACATGCAGGAGTTCACCAAATTCCCCACCAAAACT GGCCGAAGATCTTTGTCTCGCTCGATCTCACAGTCCTCCACTGACAGCTACAGTTCAGCTGCATCCTACACAGATAGCTCTGATGATGAG GTTTCTCCCCGAGAGAAGCAGCAAACCAACTCCAAGGGCAGCAGCAATTTCTGTGTGAAGAACATCAAGCAGGCAGAATTTGGACGCCGG GAGATTGAGATTGCAGAGCAAGACATGTCTGCTCTGATTTCACTCAGGAAACGTGCTCAGGGGGAGAAGCCCTTGGCTGGTGCTAAAATA GTGGGCTGTACACACATCACAGCCCAGACAGCGGTGTTGATTGAGACACTCTGTGCCCTGGGGGCTCAGTGCCGCTGGTCTGCTTGTAAC ATCTACTCAACTCAGAATGAAGTAGCTGCAGCACTGGCTGAGGCTGGAGTTGCAGTGTTCGCTTGGAAGGGCGAGTCAGAAGATGACTTC TGGTGGTGTATTGACCGCTGTGTGAACATGGATGGGTGGCAGGCCAACATGATCCTGGATGATGGGGGAGACTTAACCCACTGGGTTTAT AAGAAGTATCCAAACGTGTTTAAGAAGATCCGAGGCATTGTGGAAGAGAGCGTGACTGGTGTTCACAGGCTGTATCAGCTCTCCAAAGCT GGGAAGCTCTGTGTTCCGGCCATGAACGTCAATGATTCTGTTACCAAACAGAAGTTTGATAACTTGTACTGCTGCCGAGAATCCATTTTG GATGGCCTGAAGAGGACCACAGATGTGATGTTTGGTGGGAAACAAGTGGTGGTGTGTGGCTATGGTGAGGTAGGCAAGGGCTGCTGTGCT GCTCTCAAAGCTCTTGGAGCAATTGTCTACATTACCGAAATCGACCCCATCTGTGCTCTGCAGGCCTGCATGGATGGGTTCAGGGTGGTA AAGCTAAATGAAGTCATCCGGCAAGTCGATGTCGTAATAACTTGCACAGGAAATAAGAATGTAGTGACACGGGAGCACTTGGATCGCATG AAAAACAGTTGTATCGTATGCAATATGGGCCACTCCAACACAGAAATCGATGTGACCAGCCTCCGCACTCCGGAGCTGACGTGGGAGCGA GTACGTTCTCAGGTGGACCATGTCATCTGGCCAGATGGCAAACGAGTTGTCCTCCTGGCAGAGGGTCGTCTACTCAATTTGAGCTGCTCC ACAGTTCCCACCTTTGTTCTGTCCATCACAGCCACAACACAGGCTTTGGCACTGATAGAACTCTATAATGCACCCGAGGGGCGATACAAG CAGGATGTGTACTTGCTTCCTAAGAAAATGGATGAATACGTTGCCAGCTTGCATCTGCCATCATTTGATGCCCACCTTACAGAGCTGACA GATGACCAAGCAAAATATCTGGGACTCAACAAAAATGGGCCATTCAAACCTAATTATTACAGATACTAATGGACCATACTACCAAGGACC AGTCCACCTGAACCACACACTCTAAAGAAATATTTTTTAAGATAACTTTTATTTTCTTCTTACTCCTTTCCTCTTGATTTTTTTCCTATA ATTTCATTCTTGTTTTTTCATCTCATTATCCAAGTTCTGCAGACCACACAGGAACTTGCTTCATGGCTCTTTAGATGAAATAGAAGTTCA GGGTTCCTCACTCTAGTCACTAAAGAAGGATTTTACTCTCCCAGCCCAGAAAGGTGATTCTTTCTTTACCATTTCTGGGGACTTTAGTCT TAATTAGGTACCTTATTAACAGGAAATGCTAAGGTACCTTCTCTGTGGAACAATCTGCAATGTCTAAATCGCCTTAAAAGAGCCCATTTC TTAGCTGCTGAAATCAGTGCTCTTTCACTTCTTCAGAGAAGCAGGGATGGTACCTACCCGGCAGGTAGGTTAGATGTGGGTGGTGCATGT TAATTTCCCTTAGAAGTTCCAAGCCCTGTTTCCTGCGTAAAGGTGGTATGTCCAGTTCAGAGATGTGTATAATGAGCATGGCTTGTTAAG ATCAGGAGGCCCACTTGGATTTATAGTATAGCCCTTCCTCCACTCCCACCAGACTTGCTCATTTTTCGAGTTTTTAACTAGACTACACTC TATTGAGTTTAATTTTGTCCTCTAGGATTTATTTCTGTTGTCCAAAAAAAAAAAAAAAGAAAAGAAAAATTAAGGAGAATTTTTGGTGTT AATGCTGAGGAATTGCTTGAGTGGTTAGTTGTTACCAATTTCTCTTTTGAACCTTTGGAGCTAAGGATGCTGAGTCTAGAGAAATGCTAG TCTCAAGCCCTGTTAAGTCCCTCTGTTTCTAGCCCGTAGTTCATAGCATCAGTGAACTGGAGCCACAACAGCAAATTCTATCAGCTGTGT ACCATACAGCTTGTGCTGAAGGCGAATTTCTTGAGCCATTACTCAGTATAAAGCACTGAGTTCTATCTTTAGGATTTATCTTTAAGAGCA AATTTCTGGTCAGCTGTGCTTCTGCAACCTAAAATATTTAAAGGGAGGTAGGTGTGGGCAGGAGGAGGAATGATAAATTGGGCCAGGGCA AGAAAAATCTAGCTTCATATAATTTGTCTGGGACTATACACCCTATATAATGTTAGTTTTACAGAAGTAATATGACTTTTGATTGCTACA TACCACAAAGAGTTTATGAACTGAGATCATAAAGGGCAACTGATGTGTGAAGAAAGTAGTCAGTACATCCTGGCTCATGCTCTGAAAGAA TATCCAGAGAGGCTCTCTCAAAGATCAGGGAGATGTATTCCCATGCCATGCACCCTGCTTCCCAGCATTTCTGCATGGTCAAGTGAGCTT TATGCTCATGAGCTTTAAGTATATAATTATCCAGGATTTTAAATCCTCAACTTGTTCTAGCTTGTGATCCCTCAAAGTTGGGTCATACGT TAGTGCTAGATACTAGAAATTTTCACTTTTCCACTGATCAGAGAGACAGACATTAAAAACAAAAATAGAAGAAAGGAAAGCTTTCACCCT GCAGCTTCTTAGCAGGGAACAATTGTCTTGCCAAAACTTTTTTCCCTTTTCTCTCCCATTTTCTTTTACCCAATCCCTTCTTACTCCTTG CCAGTGTGACCATGCTTTCTTCTCTGTAGATGTTAACAGTTAAGGCCTATTTTCCTCGGGCACTTAACCAACCAATCAGAACACCACATC TGTTAGGGGAGGTAACCTGGCCAACAGTGTATCCATCACGTTAGCCCTGCTGGAGGGAAGGGACCCACATTCACCTGCCCTCTGACCTGC CCCTTGATCCCATATCTATTACCGTGTCCATAGGAATAATAGGTAAGGGCTCTGTCTCTGTCAAGCCATGTAACAAAGGACACTGTTAAA AAAAAAAAAAAGTCTGGCATCAGAGGGAGCATGTGGAGAGCAACTTGGGAAGAACAAGTTCATTTTGTATTGAATGATTTTTAATGAATG >96412_96412_1_UBQLN4-AHCYL1_UBQLN4_chr1_156011275_ENST00000368309_AHCYL1_chr1_110551655_ENST00000369799_length(amino acids)=1041AA_BP=551 MAEPSGAETRPPIRVTVKTPKDKEEIVICDRASVKEFKEEISRRFKAQQDQLVLIFAGKILKDGDTLNQHGIKDGLTVHLVIKTPQKAQD PAAATASSPSTPDPASAPSTTPASPATPAQPSTSGSASSDAGSGSRRSSGGGPSPGAGEGSPSATASILSGFGGILGLGSLGLGSANFME LQQQMQRQLMSNPEMLSQIMENPLVQDMMSNPDLMRHMIMANPQMQQLMERNPEISHMLNNPELMRQTMELARNPAMMQEMMRNQDRALS NLESIPGGYNALRRMYTDIQEPMFSAAREQFGNNPFSSLAGNSDSSSSQPLRTENREPLPNPWSPSPPTSQAPGSGGEGTGGSGTSQVHP TVSNPFGINAASLGSGMFNSPEMQALLQQISENPQLMQNVISAPYMRSMMQTLAQNPDFAAQMMVNVPLFAGNPQLQEQLRLQLPVFLQQ MQNPESLSILTNPRAMQALLQIQQGLQTLQTEAPGLVPSLGSFGISRTPAPSAGSNAGSTPEAPTSSPATPATSSPTGASSAQQQLMQQM IQLLAGSGNSQQIQFADDMQEFTKFPTKTGRRSLSRSISQSSTDSYSSAASYTDSSDDEVSPREKQQTNSKGSSNFCVKNIKQAEFGRRE IEIAEQDMSALISLRKRAQGEKPLAGAKIVGCTHITAQTAVLIETLCALGAQCRWSACNIYSTQNEVAAALAEAGVAVFAWKGESEDDFW WCIDRCVNMDGWQANMILDDGGDLTHWVYKKYPNVFKKIRGIVEESVTGVHRLYQLSKAGKLCVPAMNVNDSVTKQKFDNLYCCRESILD GLKRTTDVMFGGKQVVVCGYGEVGKGCCAALKALGAIVYITEIDPICALQACMDGFRVVKLNEVIRQVDVVITCTGNKNVVTREHLDRMK NSCIVCNMGHSNTEIDVTSLRTPELTWERVRSQVDHVIWPDGKRVVLLAEGRLLNLSCSTVPTFVLSITATTQALALIELYNAPEGRYKQ -------------------------------------------------------------- >96412_96412_2_UBQLN4-AHCYL1_UBQLN4_chr1_156011276_ENST00000368309_AHCYL1_chr1_110551656_ENST00000369799_length(transcript)=5274nt_BP=1746nt GTTGGAGGCGCAGAAGCCGAGCCGGGCCGGCCGGGCGGGCGGGGAGGAGGAGGAGCCGGGCGGGCTGGCGGGCGGCCGGGTGGCGGCGGC GGCATGGCGGAGCCGAGCGGGGCCGAGACGAGGCCCCCCATTCGGGTCACCGTCAAGACCCCCAAGGACAAGGAGGAAATTGTGATCTGC GATCGAGCCTCGGTCAAGGAGTTCAAAGAGGAAATCTCCCGGAGGTTTAAGGCTCAGCAGGATCAGCTGGTCCTGATCTTCGCAGGCAAG ATCCTCAAGGATGGGGACACACTGAACCAGCACGGAATCAAGGACGGGCTCACTGTCCATCTGGTCATCAAGACCCCTCAGAAGGCTCAA GATCCAGCTGCTGCCACTGCTTCTTCCCCCTCCACACCTGACCCTGCCTCAGCACCCTCCACCACGCCTGCTTCACCCGCCACCCCTGCC CAGCCCTCCACCTCTGGCAGTGCCTCTTCAGATGCTGGCAGTGGAAGCCGGAGGAGCAGTGGTGGGGGGCCCTCTCCGGGGGCTGGGGAG GGATCCCCCAGTGCTACTGCGTCCATACTCTCTGGCTTTGGGGGCATCCTGGGGCTGGGCAGCCTAGGCCTGGGCTCTGCCAACTTCATG GAGCTGCAGCAGCAGATGCAGCGGCAGCTGATGTCCAATCCTGAGATGCTGTCACAGATCATGGAGAACCCCCTGGTCCAGGATATGATG TCTAACCCTGATCTGATGCGTCACATGATTATGGCCAACCCCCAGATGCAGCAGTTGATGGAGCGGAACCCTGAGATCAGCCACATGCTC AATAACCCTGAACTCATGAGGCAGACAATGGAGCTTGCTCGGAATCCAGCCATGATGCAAGAGATGATGCGGAACCAGGACCGGGCCCTG AGCAACCTTGAGAGCATCCCTGGAGGGTATAATGCCCTCCGCCGCATGTACACGGACATCCAGGAGCCCATGTTCAGTGCTGCCCGGGAA CAGTTTGGCAACAATCCCTTCTCTTCCCTGGCCGGGAACTCCGACAGCTCATCCTCCCAGCCTCTGCGGACTGAGAATCGAGAGCCCCTC CCTAACCCCTGGAGCCCCTCGCCCCCCACCTCCCAGGCCCCCGGGTCCGGTGGGGAGGGCACCGGAGGATCGGGGACCAGCCAGGTGCAC CCGACAGTCTCGAACCCCTTTGGGATCAATGCGGCTAGCCTGGGGTCAGGGATGTTCAATAGCCCAGAAATGCAAGCCCTCCTCCAGCAG ATCTCTGAGAACCCCCAGCTGATGCAGAATGTGATCTCAGCACCCTACATGCGCAGCATGATGCAGACGCTTGCCCAGAACCCCGACTTT GCTGCTCAGATGATGGTGAATGTGCCGCTCTTCGCGGGGAACCCCCAACTGCAGGAGCAGCTCCGCCTGCAGCTCCCAGTCTTCCTGCAG CAGATGCAGAACCCAGAGTCACTCTCCATCCTTACCAATCCCCGAGCCATGCAGGCATTGCTGCAGATCCAGCAGGGACTACAGACCTTG CAGACCGAGGCCCCTGGGCTGGTACCCAGCCTTGGCTCCTTTGGGATATCCCGGACCCCAGCACCCTCAGCAGGCAGCAACGCAGGGTCT ACGCCCGAGGCCCCCACTTCCTCACCAGCCACGCCAGCCACATCTTCTCCAACAGGGGCTTCCAGCGCCCAGCAGCAACTCATGCAGCAG ATGATCCAGCTTTTGGCTGGAAGTGGAAACTCACAGCAAATCCAGTTTGCTGATGACATGCAGGAGTTCACCAAATTCCCCACCAAAACT GGCCGAAGATCTTTGTCTCGCTCGATCTCACAGTCCTCCACTGACAGCTACAGTTCAGCTGCATCCTACACAGATAGCTCTGATGATGAG GTTTCTCCCCGAGAGAAGCAGCAAACCAACTCCAAGGGCAGCAGCAATTTCTGTGTGAAGAACATCAAGCAGGCAGAATTTGGACGCCGG GAGATTGAGATTGCAGAGCAAGACATGTCTGCTCTGATTTCACTCAGGAAACGTGCTCAGGGGGAGAAGCCCTTGGCTGGTGCTAAAATA GTGGGCTGTACACACATCACAGCCCAGACAGCGGTGTTGATTGAGACACTCTGTGCCCTGGGGGCTCAGTGCCGCTGGTCTGCTTGTAAC ATCTACTCAACTCAGAATGAAGTAGCTGCAGCACTGGCTGAGGCTGGAGTTGCAGTGTTCGCTTGGAAGGGCGAGTCAGAAGATGACTTC TGGTGGTGTATTGACCGCTGTGTGAACATGGATGGGTGGCAGGCCAACATGATCCTGGATGATGGGGGAGACTTAACCCACTGGGTTTAT AAGAAGTATCCAAACGTGTTTAAGAAGATCCGAGGCATTGTGGAAGAGAGCGTGACTGGTGTTCACAGGCTGTATCAGCTCTCCAAAGCT GGGAAGCTCTGTGTTCCGGCCATGAACGTCAATGATTCTGTTACCAAACAGAAGTTTGATAACTTGTACTGCTGCCGAGAATCCATTTTG GATGGCCTGAAGAGGACCACAGATGTGATGTTTGGTGGGAAACAAGTGGTGGTGTGTGGCTATGGTGAGGTAGGCAAGGGCTGCTGTGCT GCTCTCAAAGCTCTTGGAGCAATTGTCTACATTACCGAAATCGACCCCATCTGTGCTCTGCAGGCCTGCATGGATGGGTTCAGGGTGGTA AAGCTAAATGAAGTCATCCGGCAAGTCGATGTCGTAATAACTTGCACAGGAAATAAGAATGTAGTGACACGGGAGCACTTGGATCGCATG AAAAACAGTTGTATCGTATGCAATATGGGCCACTCCAACACAGAAATCGATGTGACCAGCCTCCGCACTCCGGAGCTGACGTGGGAGCGA GTACGTTCTCAGGTGGACCATGTCATCTGGCCAGATGGCAAACGAGTTGTCCTCCTGGCAGAGGGTCGTCTACTCAATTTGAGCTGCTCC ACAGTTCCCACCTTTGTTCTGTCCATCACAGCCACAACACAGGCTTTGGCACTGATAGAACTCTATAATGCACCCGAGGGGCGATACAAG CAGGATGTGTACTTGCTTCCTAAGAAAATGGATGAATACGTTGCCAGCTTGCATCTGCCATCATTTGATGCCCACCTTACAGAGCTGACA GATGACCAAGCAAAATATCTGGGACTCAACAAAAATGGGCCATTCAAACCTAATTATTACAGATACTAATGGACCATACTACCAAGGACC AGTCCACCTGAACCACACACTCTAAAGAAATATTTTTTAAGATAACTTTTATTTTCTTCTTACTCCTTTCCTCTTGATTTTTTTCCTATA ATTTCATTCTTGTTTTTTCATCTCATTATCCAAGTTCTGCAGACCACACAGGAACTTGCTTCATGGCTCTTTAGATGAAATAGAAGTTCA GGGTTCCTCACTCTAGTCACTAAAGAAGGATTTTACTCTCCCAGCCCAGAAAGGTGATTCTTTCTTTACCATTTCTGGGGACTTTAGTCT TAATTAGGTACCTTATTAACAGGAAATGCTAAGGTACCTTCTCTGTGGAACAATCTGCAATGTCTAAATCGCCTTAAAAGAGCCCATTTC TTAGCTGCTGAAATCAGTGCTCTTTCACTTCTTCAGAGAAGCAGGGATGGTACCTACCCGGCAGGTAGGTTAGATGTGGGTGGTGCATGT TAATTTCCCTTAGAAGTTCCAAGCCCTGTTTCCTGCGTAAAGGTGGTATGTCCAGTTCAGAGATGTGTATAATGAGCATGGCTTGTTAAG ATCAGGAGGCCCACTTGGATTTATAGTATAGCCCTTCCTCCACTCCCACCAGACTTGCTCATTTTTCGAGTTTTTAACTAGACTACACTC TATTGAGTTTAATTTTGTCCTCTAGGATTTATTTCTGTTGTCCAAAAAAAAAAAAAAAGAAAAGAAAAATTAAGGAGAATTTTTGGTGTT AATGCTGAGGAATTGCTTGAGTGGTTAGTTGTTACCAATTTCTCTTTTGAACCTTTGGAGCTAAGGATGCTGAGTCTAGAGAAATGCTAG TCTCAAGCCCTGTTAAGTCCCTCTGTTTCTAGCCCGTAGTTCATAGCATCAGTGAACTGGAGCCACAACAGCAAATTCTATCAGCTGTGT ACCATACAGCTTGTGCTGAAGGCGAATTTCTTGAGCCATTACTCAGTATAAAGCACTGAGTTCTATCTTTAGGATTTATCTTTAAGAGCA AATTTCTGGTCAGCTGTGCTTCTGCAACCTAAAATATTTAAAGGGAGGTAGGTGTGGGCAGGAGGAGGAATGATAAATTGGGCCAGGGCA AGAAAAATCTAGCTTCATATAATTTGTCTGGGACTATACACCCTATATAATGTTAGTTTTACAGAAGTAATATGACTTTTGATTGCTACA TACCACAAAGAGTTTATGAACTGAGATCATAAAGGGCAACTGATGTGTGAAGAAAGTAGTCAGTACATCCTGGCTCATGCTCTGAAAGAA TATCCAGAGAGGCTCTCTCAAAGATCAGGGAGATGTATTCCCATGCCATGCACCCTGCTTCCCAGCATTTCTGCATGGTCAAGTGAGCTT TATGCTCATGAGCTTTAAGTATATAATTATCCAGGATTTTAAATCCTCAACTTGTTCTAGCTTGTGATCCCTCAAAGTTGGGTCATACGT TAGTGCTAGATACTAGAAATTTTCACTTTTCCACTGATCAGAGAGACAGACATTAAAAACAAAAATAGAAGAAAGGAAAGCTTTCACCCT GCAGCTTCTTAGCAGGGAACAATTGTCTTGCCAAAACTTTTTTCCCTTTTCTCTCCCATTTTCTTTTACCCAATCCCTTCTTACTCCTTG CCAGTGTGACCATGCTTTCTTCTCTGTAGATGTTAACAGTTAAGGCCTATTTTCCTCGGGCACTTAACCAACCAATCAGAACACCACATC TGTTAGGGGAGGTAACCTGGCCAACAGTGTATCCATCACGTTAGCCCTGCTGGAGGGAAGGGACCCACATTCACCTGCCCTCTGACCTGC CCCTTGATCCCATATCTATTACCGTGTCCATAGGAATAATAGGTAAGGGCTCTGTCTCTGTCAAGCCATGTAACAAAGGACACTGTTAAA AAAAAAAAAAAGTCTGGCATCAGAGGGAGCATGTGGAGAGCAACTTGGGAAGAACAAGTTCATTTTGTATTGAATGATTTTTAATGAATG >96412_96412_2_UBQLN4-AHCYL1_UBQLN4_chr1_156011276_ENST00000368309_AHCYL1_chr1_110551656_ENST00000369799_length(amino acids)=1041AA_BP=551 MAEPSGAETRPPIRVTVKTPKDKEEIVICDRASVKEFKEEISRRFKAQQDQLVLIFAGKILKDGDTLNQHGIKDGLTVHLVIKTPQKAQD PAAATASSPSTPDPASAPSTTPASPATPAQPSTSGSASSDAGSGSRRSSGGGPSPGAGEGSPSATASILSGFGGILGLGSLGLGSANFME LQQQMQRQLMSNPEMLSQIMENPLVQDMMSNPDLMRHMIMANPQMQQLMERNPEISHMLNNPELMRQTMELARNPAMMQEMMRNQDRALS NLESIPGGYNALRRMYTDIQEPMFSAAREQFGNNPFSSLAGNSDSSSSQPLRTENREPLPNPWSPSPPTSQAPGSGGEGTGGSGTSQVHP TVSNPFGINAASLGSGMFNSPEMQALLQQISENPQLMQNVISAPYMRSMMQTLAQNPDFAAQMMVNVPLFAGNPQLQEQLRLQLPVFLQQ MQNPESLSILTNPRAMQALLQIQQGLQTLQTEAPGLVPSLGSFGISRTPAPSAGSNAGSTPEAPTSSPATPATSSPTGASSAQQQLMQQM IQLLAGSGNSQQIQFADDMQEFTKFPTKTGRRSLSRSISQSSTDSYSSAASYTDSSDDEVSPREKQQTNSKGSSNFCVKNIKQAEFGRRE IEIAEQDMSALISLRKRAQGEKPLAGAKIVGCTHITAQTAVLIETLCALGAQCRWSACNIYSTQNEVAAALAEAGVAVFAWKGESEDDFW WCIDRCVNMDGWQANMILDDGGDLTHWVYKKYPNVFKKIRGIVEESVTGVHRLYQLSKAGKLCVPAMNVNDSVTKQKFDNLYCCRESILD GLKRTTDVMFGGKQVVVCGYGEVGKGCCAALKALGAIVYITEIDPICALQACMDGFRVVKLNEVIRQVDVVITCTGNKNVVTREHLDRMK NSCIVCNMGHSNTEIDVTSLRTPELTWERVRSQVDHVIWPDGKRVVLLAEGRLLNLSCSTVPTFVLSITATTQALALIELYNAPEGRYKQ -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for UBQLN4-AHCYL1 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000359172 | 0 | 17 | 138_201 | 0 | 484.0 | BCL2L10 | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000369799 | 0 | 17 | 138_201 | 40.0 | 531.0 | BCL2L10 | |
Tgene | AHCYL1 | chr1:156011275 | chr1:110551655 | ENST00000393614 | 0 | 17 | 138_201 | 0 | 484.0 | BCL2L10 | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000359172 | 0 | 17 | 138_201 | 0 | 484.0 | BCL2L10 | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000369799 | 0 | 17 | 138_201 | 40.0 | 531.0 | BCL2L10 | |
Tgene | AHCYL1 | chr1:156011276 | chr1:110551656 | ENST00000393614 | 0 | 17 | 138_201 | 0 | 484.0 | BCL2L10 |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for UBQLN4-AHCYL1 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for UBQLN4-AHCYL1 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |